Therini Bio Secures $39 Million to Combat Neurodegenerative Diseases
May 17, 2025, 3:33 am
Location: United States, California, San Francisco
Employees: 1-10
Founded date: 2016
Total raised: $92M
In the ever-evolving landscape of biotechnology, Therini Bio, Inc. has made headlines by securing an additional $39 million in Series A financing. This funding is a beacon of hope for those grappling with neurodegenerative diseases. Based in Sacramento, California, Therini Bio is on a mission to tackle the underlying causes of these debilitating conditions, specifically focusing on vascular dysfunction and its role in diseases like Alzheimer’s and Diabetic Macular Edema (DME).
The recent financing round, which brings Therini Bio’s total Series A funding to $75 million, attracted both new and existing investors. Notable names include Angelini Ventures and Apollo Health Ventures, alongside established backers like SV Health Investors and Eli Lilly. This diverse group of investors reflects a growing confidence in Therini Bio’s innovative approach to neurodegeneration.
At the heart of Therini Bio’s strategy is THN391, a groundbreaking monoclonal antibody designed to selectively target fibrin-mediated neuroinflammation. This is no ordinary drug; it’s a potential game-changer. By focusing on the inflammatory epitope on fibrin, THN391 aims to halt the destructive cycle of neuroinflammation that leads to neuronal damage. Think of it as a skilled surgeon, precisely cutting away the roots of a problem rather than merely treating the symptoms.
The implications of this approach are profound. Neurodegenerative diseases, often viewed as the dark shadows of aging, are exacerbated by factors like hypertension and diabetes. These conditions lead to vascular dysfunction, which in turn causes toxic fibrin deposits to accumulate outside blood vessels. This accumulation triggers chronic neuroinflammation, a silent killer of neurons. Therini Bio’s mission is to shine a light on this issue and offer a solution.
In preclinical studies, THN391 has shown promise in preventing both vascular and neuronal degeneration. The results are encouraging. In a recent Phase 1a trial, the drug was well-tolerated among healthy volunteers, with no adverse effects on blood coagulation or other hematological parameters. This is crucial; a drug that can effectively treat neuroinflammation without disrupting normal blood functions is akin to finding a needle in a haystack.
With the recent funding, Therini Bio is poised to advance to Phase 1b trials, where THN391 will be tested in patients suffering from Alzheimer’s and DME. This next step is critical. It’s where hope meets reality. The company’s experienced team, led by CEO Tara Nickerson, is ready to embark on this journey. Nickerson’s background in biotech financing adds a layer of confidence to the endeavor. She understands the stakes and the potential impact of their work.
The support from investors is not just financial; it’s a partnership in a shared vision. Investors like Angelini Ventures recognize the importance of addressing the vascular and inflammatory drivers of neurodegenerative diseases. Their commitment underscores a collective belief in Therini Bio’s innovative approach. It’s a testament to the power of collaboration in the biotech sector.
As the world grapples with an aging population, the urgency to find effective treatments for neurodegenerative diseases has never been greater. Alzheimer’s disease alone affects millions, leaving families in despair. The traditional methods of treatment often fall short, focusing on managing symptoms rather than addressing root causes. Therini Bio’s approach is a refreshing departure from this norm.
The potential of THN391 extends beyond Alzheimer’s. Its application in treating Diabetic Macular Edema opens new avenues for patients suffering from vision loss due to diabetes. This dual focus on neurodegeneration and retinal diseases positions Therini Bio as a pioneer in the field. It’s like casting a wide net in a sea of possibilities, hoping to catch the most elusive fish.
The road ahead is fraught with challenges. Clinical trials are unpredictable, and the path to approval is long. However, the initial data surrounding THN391 is promising. With each step forward, Therini Bio inches closer to transforming the treatment landscape for neurodegenerative diseases. The company’s innovative approach could redefine how we understand and treat these conditions.
In conclusion, Therini Bio’s recent funding marks a significant milestone in the fight against neurodegenerative diseases. With a strong financial backing and a groundbreaking therapeutic candidate, the company is set to make waves in the biotech industry. As they prepare for Phase 1b trials, the hope is palpable. For patients and families affected by Alzheimer’s and DME, Therini Bio represents a flicker of light in a dark tunnel. The journey is just beginning, but the destination could change lives.
The recent financing round, which brings Therini Bio’s total Series A funding to $75 million, attracted both new and existing investors. Notable names include Angelini Ventures and Apollo Health Ventures, alongside established backers like SV Health Investors and Eli Lilly. This diverse group of investors reflects a growing confidence in Therini Bio’s innovative approach to neurodegeneration.
At the heart of Therini Bio’s strategy is THN391, a groundbreaking monoclonal antibody designed to selectively target fibrin-mediated neuroinflammation. This is no ordinary drug; it’s a potential game-changer. By focusing on the inflammatory epitope on fibrin, THN391 aims to halt the destructive cycle of neuroinflammation that leads to neuronal damage. Think of it as a skilled surgeon, precisely cutting away the roots of a problem rather than merely treating the symptoms.
The implications of this approach are profound. Neurodegenerative diseases, often viewed as the dark shadows of aging, are exacerbated by factors like hypertension and diabetes. These conditions lead to vascular dysfunction, which in turn causes toxic fibrin deposits to accumulate outside blood vessels. This accumulation triggers chronic neuroinflammation, a silent killer of neurons. Therini Bio’s mission is to shine a light on this issue and offer a solution.
In preclinical studies, THN391 has shown promise in preventing both vascular and neuronal degeneration. The results are encouraging. In a recent Phase 1a trial, the drug was well-tolerated among healthy volunteers, with no adverse effects on blood coagulation or other hematological parameters. This is crucial; a drug that can effectively treat neuroinflammation without disrupting normal blood functions is akin to finding a needle in a haystack.
With the recent funding, Therini Bio is poised to advance to Phase 1b trials, where THN391 will be tested in patients suffering from Alzheimer’s and DME. This next step is critical. It’s where hope meets reality. The company’s experienced team, led by CEO Tara Nickerson, is ready to embark on this journey. Nickerson’s background in biotech financing adds a layer of confidence to the endeavor. She understands the stakes and the potential impact of their work.
The support from investors is not just financial; it’s a partnership in a shared vision. Investors like Angelini Ventures recognize the importance of addressing the vascular and inflammatory drivers of neurodegenerative diseases. Their commitment underscores a collective belief in Therini Bio’s innovative approach. It’s a testament to the power of collaboration in the biotech sector.
As the world grapples with an aging population, the urgency to find effective treatments for neurodegenerative diseases has never been greater. Alzheimer’s disease alone affects millions, leaving families in despair. The traditional methods of treatment often fall short, focusing on managing symptoms rather than addressing root causes. Therini Bio’s approach is a refreshing departure from this norm.
The potential of THN391 extends beyond Alzheimer’s. Its application in treating Diabetic Macular Edema opens new avenues for patients suffering from vision loss due to diabetes. This dual focus on neurodegeneration and retinal diseases positions Therini Bio as a pioneer in the field. It’s like casting a wide net in a sea of possibilities, hoping to catch the most elusive fish.
The road ahead is fraught with challenges. Clinical trials are unpredictable, and the path to approval is long. However, the initial data surrounding THN391 is promising. With each step forward, Therini Bio inches closer to transforming the treatment landscape for neurodegenerative diseases. The company’s innovative approach could redefine how we understand and treat these conditions.
In conclusion, Therini Bio’s recent funding marks a significant milestone in the fight against neurodegenerative diseases. With a strong financial backing and a groundbreaking therapeutic candidate, the company is set to make waves in the biotech industry. As they prepare for Phase 1b trials, the hope is palpable. For patients and families affected by Alzheimer’s and DME, Therini Bio represents a flicker of light in a dark tunnel. The journey is just beginning, but the destination could change lives.